Compare Novavax Inc (NVAX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard Growth Index Fund ETF — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Vanguard Growth Index Fund ETF trades at $87.91. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | VUG | |
|---|---|---|
Market Cap | $1.68B | — |
Sector | Health | Sector/Thematic |
52-Week High | $11.19 | $90.29 |
52-Week Low | $6.22 | $70.00 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
VUG trades at $88.12, down 0.37% on the day, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights institutional accumulation, with multiple advisors increasing stakes in Q2 2026. The fund's growth focus contrasts with value counterparts underperforming this year, as noted by financial media.
The outlook remains positive given strong institutional interest and low-fee structure, though risks include market volatility and sector concentration. Growth ETFs face competition, but VUG's large-cap exposure offers stability amid bullish market forecasts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
